Role of angiogenesis on uterine fibroids therapy: Review

Mahfoudh AL-Musali Mohammed Abdulghani


Pharmacology & Toxicology department, Unaizah College of Pharmacy, Qassim University, Unaizah, 51911, Saudi Arabia.

*Corresponding Author. E-mail:


Angiotherapy, 2017, 1(1), 022–026. (Received 16 March 2017, Published 10 May 2017).


Citation: Mahfoudh AL-Musali Mohammed Abdulghani . (2017). Role of Angiogenesis on Uterine Fibroids Therapy: review. Angiotherapy, 1(1), pages 022-026.


Anti-angiogenic agents have recently been used in the treatment of cancer in combination with chemotherapy as angiogenesis is very well documented to be a powerful control point in tumour development. The growth of uterine fibroids was recently shown to be dependent on angiogenesis and different angiogenic factors involved in uterine fibroids are expressed in leiomyoma. Uterine fibroid (uterine leiomyomas) is one of the causes of infertility and is associated with recurrent miscarriages. Pathologically uterine fibroid is a benign tumours arising from the uterine myometrial compartment. Common treatments for fibroids include pharmacotherapy and non-pharmacotherapy treatments partly via anti-angiogenic mechanisms. In conclusion, direct anti-angiogenic agents may contribute to fibroid treatment. Unfortunately, there lacks good in vivo and in vitro models of uterine fibroid. Further research into developing experimental model to study uterine fibroid will aid in better understanding this disease.


Keywords: Angiogenic Factors, Uterine Fibroids, uterine leiomyomas